Please check your internet connection and try again.
# Mylotat
## Overview
Mylotat is a brand name for etofylline. Etofilline is a xanthine derivative that acts as a bronchodilator.
## Primary Indications
* Bronchospasm associated with asthma and chronic obstructive pulmonary disease (COPD).
## Adult Dosing
* The typical dose is 360 mg to 720 mg per day, divided into 2 or 3 doses.
* Specific dosing regimens may vary based on local protocols and patient response.
## Pediatric Dosing
* Etofilline is not commonly used in pediatric populations, and established pediatric dosing is not readily available. Use with caution and consider alternative therapies.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; dose reduction may be necessary. Data is limited.
* **Renal Impairment:** Use with caution; dose reduction may be necessary, especially in severe impairment. Data is limited.
* **Elderly:** May be more sensitive to xanthine effects; consider starting at the lower end of the adult dose range.
## Contraindications
* Hypersensitivity to etofylline or other xanthine derivatives.
* Acute myocardial infarction.
* Severe hypotension.
* Certain arrhythmias (e.g., supraventricular tachycardia).
## Adverse Effects
* **Common:** Nausea, vomiting, dyspepsia, headache, dizziness, insomnia, restlessness, irritability.
* **Serious:** Tachycardia, palpitations, arrhythmias, seizures, gastrointestinal bleeding, hyperglycemia.
## Key Drug Interactions
* **CYP1A2 Inhibitors (e.g., cimetidine, fluvoxamine):** May increase etofylline levels.
* **CYP1A2 Inducers (e.g., smoking, rifampin):** May decrease etofylline levels.
* **Beta-blockers:** May antagonize bronchodilating effects.
* **Diuretics:** May increase the risk of xanthine-induced diuresis and hypokalemia.
* **Caffeine and other xanthines:** Additive stimulant and adverse effects.
## Monitoring
* **Therapeutic Drug Monitoring:** Serum levels may be monitored, particularly if efficacy is poor or toxicity is suspected. Target serum concentrations are typically in the range of 10-20 mcg/mL, but this can vary.
* **Clinical Signs and Symptoms:** Monitor for improvement in bronchospasm and for adverse effects (cardiac, CNS, GI).
* **Renal and Hepatic Function:** Periodic assessment.
* **Electrolytes:** Particularly potassium, especially with concurrent diuretic use.
## Clinical Pearls
* Mylotat (etofylline) should be used cautiously in patients with a history of seizures, cardiac arrhythmias, peptic ulcer disease, or significant renal or hepatic impairment.
* Toxicity is related to serum concentration; monitor closely for signs and symptoms of xanthine toxicity.
* Smoking cessation can significantly increase etofylline levels, potentially leading to toxicity.
***
**Disclaimer:** This information is intended for clinical pharmacy professionals and is not a substitute for professional medical advice. Always verify current prescribing information and consult with a qualified healthcare provider before making any treatment decisions.
